You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201461 - 201470 of 204455 results
  1. Antibody-Membrane Switch (AMS) technology for optimized antibody engineering

    SBC: Panorama Research Incorporated            Topic: NIAID

    Abstract Generation of high productivity cell lines remains a major bottleneck in therapeutic antibody engineering. To address this need, we have developed a proprietary Antibody-Membrane Switch (AMS) technology that facilitates rapid cloning of cell lines for commercial production of antibodies. This technology streamlines identification of high-productivity clones, shaving at least 6-8 months o ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. A Therapeutic for Radiation Induced Lung Injury

    SBC: Angion Biomedica Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Self-Contained Assay Device for Rapid Detection of Viable Cryptosporidium in Wa

    SBC: Biodetection Instruments, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): This Small Business Innovation Research Phase I project will investigate the technical feasibility of an in vitro excystation-based automated cartridge assay for rapid detection of viable Cryptosporidium oocysts in water. Briefly, viable oocysts will be subjected to an in vitro excystation step to release sporozoites and the antigens for detection on a patent-p ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    SBC: EVRYS BIO LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC Interim Adjusted Estimates of Seasonal Influenza Vaccine Effectiveness reported overall vaccine effectiveness of 56% and 67% against influenza A and B infections, respectively, with much reduced effect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Biosensor Assays for Diagnosis of Chronic HCV Infection

    SBC: ALDERON BIOSCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR application is submitted in response to the call by DHHS for new tests for qualitative measurement of HCV RNA for diagnosis of chronic HCV infection in patients. The need is for HCV RNA assays that areas reliable but less expensive and resource-demanding than current molecular assays. The new test proposed for research and development consists ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Transcriptional silencing of latent HIV infection- a novel small molecule class

    SBC: SIRENAS MARINE DISCOVERY, LLC            Topic: NIAID

    DESCRIPTION: Though highly effective in changing the course of the global HIV epidemic, current Antiretroviral Therapy (ART) fails to eradicate the infection completely. This has led to the emergence of drug-resistant mutant strains, the phenomenon of latent disease and a number of adherence and toxicity issues associate with long-term therapy. Novel compounds that inhibit transcription from integ ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Destroying the HIV-1 provirus by utilizing components of the CRISPR/Cas system

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this project is to develop a plasmid-based therapy that will destroy the integrated HIV-1 DNA (HIV- 1 provirus) in infected cells. Current HIV-1 anti-retroviral therapy (ARV) consists of a cocktail of drugsthat blocks viral binding and replication, but does not destroy the HIV-1 provirus. In addition, ARV does not impact the large reservoir of laten ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Glycoengineered baculoviruses for the production of more efficacious influenza va

    SBC: Glycobac, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vacci ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this proposal is to adapt a technology that we have developed for monitoring residual disease in leukemia patients to monitor residual autoimmune disease in Celiac Disease patients. Celiac disease hasa significant burden on quality of life, as it is one of the most frequent autoimmune diseases, with an estimated prevalence of approximately 1% ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Engineering of a Novel CDN Nanoparticle Platform

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): For many years, the use of protein and peptide antigens to induce specific immune responses has been an area of intense effort with the goal of developing improved vaccines. In principle, this approach is attractive because it has the potential to provide immunological specificity, tighter control of manufacturing processes, and elimination of most of the secon ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government